Objectives: Inhibition of the organic cation transporter-2 renal tubule transporter by dolutegravir leads to serum creatinine increase. Serum cystatin C is a non-organic cation transporter-2-dependent marker, possibly enabling glomerular filtration rate (GFR) estimation under dolutegravir. Our goal was to evaluate the changes in creatinine-and cystatin C-based estimated GFR values before and after dolutegravir initiation.
Introduction
Dolutegravir is one of the most recent integrase inhibitors, having shown high efficacy in naive and pretreated HIV-1-infected patients. 1 Triple and dual ART regimens including dolutegravir are increasingly being used. 2 Dolutegravir inhibits the organic cation transporter (OCT)-2 and plasma creatinine is excreted through this transporter, leading to plasma creatinine increase at treatment initiation. Studies assessing dolutegravir efficacy have highlighted a stable plasma creatinine increase of 10 lmol/L as early as week 2-3. 3 Estimated glomerular filtration rate (eGFR) is falsely decreased in this context when assessed with plasma creatinine-based equations (MDRD or CKD-EPI creat ). A Phase I study proved that measured GFR (mGFR) remained unchanged after dolutegravir initiation, using non-OCT-2-dependent isotopic markers. 4 Monitoring renal function in patients on a dolutegravir-based ART regimen is a daily clinical concern.
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Cystatin C is a low molecular weight plasma protein freely filtered by the glomerulus. Its production is independent of gender, muscle mass, dietary influences and nyctohemeral period, and could be influenced by inflammation, thyroid dysfunction and smoking. [5] [6] [7] [8] Cystatin C is a non-OCT-2-dependent routinely available marker, which enables GFR estimation with a validated equation (CKD-EPI cyst ). 9 Our goal was to evaluate the changes in creatinine-and cystatin-based eGFR values after dolutegravir initiation, in HIVinfected patients from a French reference centre.
Methods
This study was conducted at Pitié-Salpêtrière Hospital, Paris, France, in March 2017. All HIV-1-infected patients were eligible if dolutegravir-based ART had been initiated between October 2016 and March 2017. They were included if at least one routine frozen plasma sample was available at the hospital laboratory before and after dolutegravir initiation (0-90 days before and 21-180 days after). Patients with systemic inflammation [Creactive protein (CRP) .5 mg/L] or known thyroid dysfunction were not included.
Plasma creatinine, cystatin C and CRP were measured from frozen plasma samples, as stability has been demonstrated after 6 months. Creatinine assay was performed on the Roche-Hitachi P-Module instrument using the Jaffe compensated method standardized against ID/MS. Cystatin C assay was performed on the Roche-Cobas 6000 instrument using the Diagam immunoturbidimetric method standardized against plasma reference material ERM-DA471/IFCC. CRP assay was performed on the RocheHitachi P-Module instrument using the particle-enhanced turbidimetric method standardized against the reference preparation CRM 470.
CKD-EPI creat and CKD-EPI cyst equations were used to estimate creatinine-and cystatin-based GFR, as described elsewhere. 9 Plasma creatinine and cystatin C values, and creatinine-and cystatin C-based eGFR values were expressed as mean + SD. Variations of these parameters after dolutegravir initiation were analysed by paired t-test. The analyses of creatinine-based eGFR and plasma viral load (pVL) at baseline were conducted for all patients and then in different subgroups.
Routine clinical data were recorded in the Nadis database and informed consent was obtained from all patients.
Results

Patient characteristics
One hundred and seventy-six patients were eligible (dolutegravir initiation in the last 6 months) and 44 patients were included (two available frozen plasma samples, as described earlier), after exclusion of 10 patients with CRP .5 mg/L (Table 1) . No one had thyroid dysfunction. Six patients were ART-naive, with a median pVL of 4.8 log 10 copies/mL (IQR 4.3-5.2). Thirty-eight were pretreated, with a median ART duration of 13 years (IQR [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , and among them 28 (74%) had pVL ,50 copies/mL. Data on microalbuminuria or proteinuria were not available. After dolutegravir initiation, the number of patients with tenofovir-, cobicistat-and rilpivirinebased ART was equal or lower than before dolutegravir initiation (Table 1) . Reasons for ART switch were: simplification for single tablet regimen in 13 patients (34%); renal, metabolic or bone toxicity in 9 (24%); virological failure in 8 (21%); and prevention of toxicity in 8 (21%). Renal toxicity affected three patients, of whom the first received tenofovir/emtricitabine ! rilpivirine and the other two received tenofovir/emtricitabine ! elvitegravir/cobicistat.
Plasma creatinine and cystatin C values and associated eGFR at baseline
Samples were assessed for a median of 9 days (IQR 2-17) before dolutegravir initiation and 41 days (IQR 29-72) after dolutegravir initiation.
The mean plasma creatinine value was 85.6 lmol/L (+21.5), with a mean associated eGFR of 91.5 mL/min/1.73 m 2 (+22.8), whereas the mean plasma cystatin C value was 0.80 mg/L (+0.29), with a mean associated eGFR of 106.2 mL/min/1.73 m 2 (+30.0) ( Table 2) .
Nineteen patients (43%) had a creatinine-based eGFR of ,90 mL/min/1.73 m 2 and 11 (25%) had a cystatin C-based eGFR of . Three and two patients had a creatinineand cystatin C-based eGFR of ,60 mL/min, respectively.
Variations in plasma creatinine and cystatin C values and associated eGFR
After dolutegravir initiation, plasma creatinine values significantly increased (!8.6 lmol/L, 95% CI !5.8; !11.4, P , 0.001) and associated eGFR significantly decreased (#7.7 mL/min/1.73 m 2 , 95% CI #10.4; #5.1, P , 0.001) ( Figure 1 and Table 2 ). In contrast, there was no significant variation in cystatin C values (#0.03 mg/L, 95% CI #0.12; !0.06, P " 0.50) or associated eGFR (!2.5 mL/min/ 1.73 m 2 , 95% CI #6.3; !11.3, P " 0.57) ( Figure 1 and Table 2 ). Palich et al.
Variations in creatinine values and associated eGFR were statistically significant in the subgroups of patients with creatininebased eGFR ,90 mL/min/1.73 m 2 or 90 mL/min/1.73 m 2 and in the subgroup of patients with pVL .50 copies/mL ( Figure 1 and Table 2 ). There were no significant changes in cystatin C values and associated eGFR in any of these subgroups ( Figure 1 and Table 2 ).
Discussion
Our results showed that plasma cystatin C levels were not affected by dolutegravir use in HIV-infected patients, whereas plasma creatinine levels significantly increased over the same period. Consequently, cystatin-based eGFR could be a better option to assess renal function in dolutegravir-treated patients. These results confirm recent findings from Japan. [10] [11] [12] Dolutegravir is increasingly being prescribed as it is included in a fixed combination without tenofovir (abacavir/lamivudine ! dolutegravir) and in several effective dual therapies (particularly lamivudine ! dolutegravir and rilpivirine ! dolutegravir). 13 Our study population reflects the changes in prescriptions over time. Accuracy of renal function monitoring under ART is an important clinical issue in patients with a high risk of worsening renal function. HIV-infected patients are an ageing population, with a growing number of comorbidities leading to renal impairment, and cancers, with sometimes the need for nephrotoxic treatments (such as chemotherapies).
14 Our study population reflects the current dolutegravir-treated population, with 10 patients .60 years old and a significant prevalence of high blood pressure and diabetes. This population is poorly represented in clinical trials. Here, the variation in markers of renal function was not dependent on the eGFR at baseline.
Assessment of renal function at baseline highlighted discrepancies between creatinine-and cystatin C-based eGFR. Mean cystatin C-based eGFR was higher than the mean creatinine-based eGFR. Relevance of cystatin C measurement to estimate GFR in HIVinfected patients is unclear. Several studies have compared the performance of creatinine-and cystatin C-based equations (CKD-EPI creat and CKD-EPI cyst , respectively) regarding mGFR and shown better or equivalent accuracy for the cystatin C-based equation in HIV-infected patients, [15] [16] [17] including populations of HIV-positive patients on dolutegravir. 11 However, other authors have shown that cystatin C levels are dependent on HIV replication (increase in cystatin C levels in the case of high pVL, high immune activation or low CD4 count). 18, 19 Here, we showed that our findings remained identical in the subgroup of patients with HIV replication at baseline (pVL .50 copies/mL). Data from literature show that tenofovir-, rilpivirine-and cobicistat-based regimens can also disrupt renal outcomes. 3, 20 Despite the fact that some drugs can inhibit active tubular transport, overall, in our study, modifications of drugs combined with dolutegravir did not impact cystatin C marker variation.
Plasma cystatin C is a routinely accessible and available marker, which can be used in clinical practice. In France, it is much more expensive than plasma creatinine and not yet available in all laboratories, but it is not uncommon for clinicians to be concerned Plasma cystatin C in dolutegravir-treated patients JAC about a decrease of creatinine-based eGFR, involving many supplementary dispenses for eliminating renal impairment in high-risk renal patients (biological controls, consultations, radiological exams), in case of subnormal plasma creatinine. Our study presents some limitations, including a small sample size, large range of sample timings and limited number of patients with eGFR ,60 mL/min/1.73 m 2 . A specific and prospective study centred on such patients could show the relevance of plasma cystatin C use in patients on dolutegravir with advanced renal failure. On the other hand, plasma creatinine and cystatin C were measured only once after dolutegravir initiation. However, it has been shown that the plasma creatinine increase after dolutegravir initiation occurs early and remains stable. 3, 10 To conclude, we suggest that plasma cystatin C could be used to estimate GFR variations in HIV-positive patients with a dolutegravir-based regimen, particularly for patients with multifactorial renal dysfunction.
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